Main Logo

Saad Z. Usmani, MD, MBA

About Dr. Usmani

Dr.  Usmani is a hematologist-oncologist with over 14 years of experience in managing multiple myeloma and related plasma cell disorders. He specializes in treating monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and active multiple myeloma, including high-risk and treatment-refractory cases. His clinical expertise includes bone marrow transplantation, CAR T-cell therapy, and immunotherapy.

Fluent in English, Hindi, Punjabi, and Urdu, Dr. Usmani is deeply committed to patient-centered care. He emphasizes education, empowerment, and individualized treatment planning throughout every phase of the patient journey. He is known for his empathetic communication and clinical excellence, consistently earning high praise from patients, with an average rating of 4.9 based on over 150 reviews.

Dr. Usmani actively participates in clinical research and the development of novel therapies for plasma cell diseases. He is a fellow of the American College of Physicians (FACP) and the American Society of Clinical Oncology (FASCO), reflecting his leadership and contributions to the field.

Articles by Saad Z. Usmani, MD, MBA

Saad Z. Usmani, MD, MBAMyeloma | July 24, 2025
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
View More
Saad Z. Usmani, MD, MBAMyeloma | July 3, 2025
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Saad Z. Usmani, MD, MBAMyeloma | July 24, 2025
Experts debate immune escape, inflammation, and early intervention in relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, MBAMyeloma | February 6, 2025
An expert on site at ASH 2024 discusses the MRD negativity data from CARTITUDE-4.
Saad Z. Usmani, MD, MBAThe HemOnc Pulse | November 20, 2024
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse Live | May 31, 2024
Dr. Usmani offers his take on treating smoldering myeloma and using MRD as a prognostic factor.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Usmani shares insights on the evolution in myeloma treatment since he first started practicing.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
The panelists highlight key data presented at ASCO 2023.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
Saad Z. Usmani, MD, MBAVideo Insights | March 15, 2024
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
Saad Z. Usmani, MD, MBAVideo Insights | January 17, 2024
The panel considers triplet versus quadruplet therapy for myeloma induction.
Thomas Martin, MDMyeloma | February 7, 2023
Thomas G. Martin, MD, and Saad Z. Usmani, MD, MBA, FACP, debate CAR-T vs bispecific antibodies for R/R MM.
Amrita Krishnan, MD, FACPPrint | May 30, 2023
Amrita Krishnan, MD, FACP, and Saad Z. Usmani, MD, MBA, FACP, debate if CAR-T therapy will replace AHSCT in multiple myeloma.
Saad Z. Usmani, MD, MBAMyeloma | November 14, 2022
Experts discuss treatment options related to anti-CD38 based combination triplets.
Saad Z. Usmani, MD, MBAMyeloma | November 14, 2022
Experts focus on the latest news and clinical development and impact for multiple myeloma.